Now, hope for hepatitis C liver transplant patients

Scientists have revealed that a new research could be a new hope for treating liver transplant patients with recurring hepatitis C (HCV).

The scientists gave sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) to post-liver transplant patients with recurring HCV, who had exhausted all treatment options and had poor clinical prognoses, for up to 48 weeks.

According to the study, 62 percent of the patients had improvements in clinical conditions associated with hepatic decompensation and/or improvement in liver function tests.

Patrizia Burra of the Multivisceral Transplant Unit, Padova University Hospital, Padua, Italy, said that there are no effective treatment options for this patient group, but their new trial involving the nucleotide polymerase inhibitor sofosbuvir (SOF) has demonstrated promising results, providing further evidence of its clinical potential.

Burra added that this could be a second chance for patients with advanced hepatitis C liver disease, liver transplants and for those who continue to suffer post-surgery, it's important for us to keep following up all avenues possible to improve their quality of life.

image
Business Standard
177 22
Business Standard

Now, hope for hepatitis C liver transplant patients

ANI  |  Washington 

Scientists have revealed that a new research could be a new hope for treating liver transplant patients with recurring hepatitis C (HCV).

The scientists gave sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) to post-liver transplant patients with recurring HCV, who had exhausted all treatment options and had poor clinical prognoses, for up to 48 weeks.

According to the study, 62 percent of the patients had improvements in clinical conditions associated with hepatic decompensation and/or improvement in liver function tests.

Patrizia Burra of the Multivisceral Transplant Unit, Padova University Hospital, Padua, Italy, said that there are no effective treatment options for this patient group, but their new trial involving the nucleotide polymerase inhibitor sofosbuvir (SOF) has demonstrated promising results, providing further evidence of its clinical potential.

Burra added that this could be a second chance for patients with advanced hepatitis C liver disease, liver transplants and for those who continue to suffer post-surgery, it's important for us to keep following up all avenues possible to improve their quality of life.

RECOMMENDED FOR YOU

Now, hope for hepatitis C liver transplant patients

Scientists have revealed that a new research could be a new hope for treating liver transplant patients with recurring hepatitis C (HCV).The scientists gave sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) to post-liver transplant patients with recurring HCV, who had exhausted all treatment options and had poor clinical prognoses, for up to 48 weeks.According to the study, 62 percent of the patients had improvements in clinical conditions associated with hepatic decompensation and/or improvement in liver function tests.Patrizia Burra of the Multivisceral Transplant Unit, Padova University Hospital, Padua, Italy, said that there are no effective treatment options for this patient group, but their new trial involving the nucleotide polymerase inhibitor sofosbuvir (SOF) has demonstrated promising results, providing further evidence of its clinical potential.Burra added that this could be a second chance for patients with advanced hepatitis C liver disease, liver ...

Scientists have revealed that a new research could be a new hope for treating liver transplant patients with recurring hepatitis C (HCV).

The scientists gave sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) to post-liver transplant patients with recurring HCV, who had exhausted all treatment options and had poor clinical prognoses, for up to 48 weeks.

According to the study, 62 percent of the patients had improvements in clinical conditions associated with hepatic decompensation and/or improvement in liver function tests.

Patrizia Burra of the Multivisceral Transplant Unit, Padova University Hospital, Padua, Italy, said that there are no effective treatment options for this patient group, but their new trial involving the nucleotide polymerase inhibitor sofosbuvir (SOF) has demonstrated promising results, providing further evidence of its clinical potential.

Burra added that this could be a second chance for patients with advanced hepatitis C liver disease, liver transplants and for those who continue to suffer post-surgery, it's important for us to keep following up all avenues possible to improve their quality of life.

image
Business Standard
177 22
Widgets Magazine

More News

  • Bikes image  via Shutterstock Two-wheeler majors wheel in discounts for cash-flush govt staffers
  • A man opens the shutter of a shop painted with an advertisement of Reliance Communications in Mumbai RCom launches cloud-based network platform for enterprises
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard